Form 4: TriSalus Life Sciences Director William Valle Granted 15,000 Stock Options

TriSalus Life Sciences, Inc. Director William Valle was granted 15,000 stock options with an exercise price of $5.50, vesting over one year or at the next annual stockholder meeting.

Summary

• William Valle, a Director of TriSalus Life Sciences, Inc. (TLSI), was granted 15,000 Director Stock Options on June 12, 2025.
• The exercise price for these options is $5.50 per share.
• The options are set to fully vest on the one-year anniversary of the grant date (June 12, 2026) or on the date of the Issuer's next annual stockholder meeting, whichever occurs first, contingent on Mr. Valle's continued service.
• The expiration date for these stock options is June 11, 2035.
• Following this transaction, Mr. Valle beneficially owns a total of 56,250 derivative securities (stock options) in TriSalus Life Sciences, Inc.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options aligns the director's interests with shareholders, which is generally viewed favorably. However, it is a routine compensation event and not indicative of significant new developments.

Positives

• The grant of stock options to a director helps align their interests with those of the shareholders, incentivizing long-term company performance.
• This is a standard form of compensation for directors, indicating ongoing commitment and involvement.

Future Outlook

The granted stock options are subject to a future vesting schedule, which will occur on the one-year anniversary of the grant date (June 12, 2026) or the date of the Issuer's next annual stockholder meeting, whichever is earlier, provided the director's continued service.

Management Comments

• The filing was signed by Mary Szela, Attorney-in-Fact for William Valle.

Industry Context

The grant of stock options to directors is a common practice across various industries, including life sciences, to attract, retain, and incentivize board members by linking their compensation to the company's long-term stock performance.

Comparison to Industry Standards

• Granting stock options to directors is a widely accepted compensation practice in the life sciences and biotechnology sectors, similar to companies like Moderna, BioNTech, or Gilead Sciences, which often use equity-based incentives to align director interests with shareholder value.
• The vesting schedule of one year or at the next annual meeting is a common structure for director equity awards, aiming to ensure continued engagement and oversight.

Corporate Governance

Related Party Transactions

• The grant of stock options to William Valle, a Director, constitutes a related party transaction as it involves compensation provided to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant aims to align the director's interests with shareholder value, potentially leading to better long-term performance.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The options will vest on June 12, 2026, or at the Issuer's next annual stockholder meeting, subject to William Valle's continued service.

Key Dates

Keywords

TriSalus Life Sciences, TLSI, Form 4, Stock Option Grant, Director Compensation, Insider Transaction, Equity Compensation, Beneficial Ownership